Merck announced an internal reorganization that separates its oncology business into a standalone unit as the company prepares for the anticipated loss of Keytruda exclusivity in 2028. The reorganization moves oncology into its own commercial and R&D structure while other therapeutic areas will sit in a separate specialty and infectious‑disease business. Merck named Jannie Oosthuizen president of the new oncology unit and recruited Sanofi veteran Brian Foard to lead the specialty, pharma and infectious diseases business. The company cited the need for dedicated commercial focus and leadership as the rationale for the split. Merck highlighted Keytruda’s continued commercial significance—accounting for a large share of recent pharmaceutical revenue—while signaling the move is meant to accelerate launches and pipeline execution across oncology and non‑oncology portfolios.